Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth

Ono A, Westein E, Hsiao S, Nesbitt WS, Hamilton JR, Schoenwaelder SM, Jackson SP

(2008), Blood, 112(1), 90-9

Desmoteplase-mediated plasminogen activation and clot lysis are inhibited by the lysine analogue tranexamic acid

Niego B, Horvath A, Coughlin PB, Pugsley MK, Medcalf RL

(2008), Blood Coagul Fibrinolysis, 19(4), 322-4

Refinement in the production and purification of recombinant HCMV IE1-pp65 protein for the generation of epitope-specific T cell immunity

Nguyen TH, Mifsud NA, Stewart LA, Rose MJ, Etto TL, Williamson NA, Purcell AW, Kotsimbos T, Schwarer AP

(2008), Protein Expr Purif, 61(1), 22-30

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

Newbold A, Lindemann RK, Cluse LA, Whitecross KF, Dear AE, Johnstone RW

(2008), Mol Cancer Ther, 7(5), 1066-79

Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation

Mullighan CG, Heatley SL, Danner S, Dean MM, Doherty K, Hahn U, Bradstock KF, Minchinton R, Schwarer AP, Szer J, Bardy PG

(2008), Blood, 112(5), 2120-8

A functional 14-3-3zeta-independent association of PI3-kinase with glycoprotein Ib alpha, the major ligand-binding subunit of the platelet glycoprotein Ib-IX-V complex

Mu FT, Andrews RK, Arthur JF, Munday AD, Cranmer SL, Jackson SP, Stomski FC, Lopez AF, Berndt MC

(2008), Blood, 111(9), 4580-7

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas

Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, Huang DC, Roberts AW

(2008), Proc Natl Acad Sci USA, 105(46), 17961-6

Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasmogen activator inhibitor-1 expression

Liu H, Hu Y, Simpson RW, Dear AE

(2008), J Endocrinol, 196(1), 57-65

The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma

Khong T, Sharkey J, Spencer A

(2008), Haematologica, 93(6), 860-9

Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia

Kalff A, Shortt J, Farr J, McLennan R, Lui A, Scott J, Spencer A

(2008), Haematologica, 93(1), e16-7

Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy

Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, Taylor K, Arthur C, Schwarer A, et al; Australasian Leukaemia and Lymphoma Group

(2008), Blood, 112(10), 3965-73

The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.

Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP

(2008), Cytotherapy, 10(5), 507-17

Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma

Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP

(2008), Biol Blood Marrow Transplant, 14(1), 116-24

Overlapping and distinct roles for PI3Kbeta and gamma isoforms in S1P-induced migration of human and mouse endothelial cells

Heller R, Chang Q, Ehrlich G, Hsieh SN, Schoenwaelder SM, Kuhlencordt PJ, Preissner KT, Hirsch E, Wetzker R

(2008), Cardiovasc Res, 80(1), 96-105

Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration

Guerreiro AS, Fattet S, Fischer B, Shalaby T, Jackson SP, Schoenwaelder SM, Grotzer MA, Delattre O, Arcaro A

(2008), Clin Cancer Res, 14(21), 6761-9

Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket

Frazzetto M, Suphioglu C, Zhu J, Schmidt-Kittler O, Jennings IG, Cranmer SL, Jackson SP, Kinzler KW, Vogelstein B, Thompson PE

(2008), Biochem J, 414(3), 383-90

Essential role of platelet activation via protease activated receptor 4 in tissue factor-initiated inflammation

Busso N, Chobaz-Peclat V, Hamilton J, Spee P, Wagtmann N, So A

(2008), Arthritis Res Ther, 10(2), R42

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment

Blade J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Cibeira MT, Zhuang SH, Harousseau JL, Orlowski RZ; DOXIL-MMY-3001 Study Investigators

(2008), Clin Lymphoma Myeloma, 8(6), 352-5

Physiotherapy for Cystic Fibrosis in Australia: A Consensus Statement. International Physiotherapy Group for Cystic Fibrosis, Australian Chapter.

Button BM, Holland AE

(2008), Endorsed by the Thoracic Society of Australia and New Zealand,

Thoracic Organ Transplantation

Munro PE, Hayes KJ, Aurora P

(2008), In: Pryor J, Prasad A (eds) Physiotherapy for Respiratory and Cardiac Problems - Adults and Paediatrics. Elsevier, 495-514

590 591 592 593 594